Opportunities and challenges of disease biomarkers: a new section in the journal of translational medicine

Journal of Translational Medicine

Review

Peter A Ward¹  Xiangdong Wang² 

[1] Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA;Department of Respiratory Medicine, Biomedical Research Center, Zhongshan Hospital Qing-Pu Branch, Fudan University, Shanghai, China;Clinical Bioinformatics, Lund University Hospital, Lund, Sweden;

关键词: Chronic Obstructive Pulmonary Disease;    Mass Spectrometry Imaging;    Translational Medicine;    Single Nucleotide Polymorphism Discovery;    Monitor Severity;   

DOI  :  10.1186/1479-5876-10-240

 received in 2012-08-29, accepted in 2012-11-01,  发布年份 2012

来源: Springer

【 摘 要 】

Disease biomarkers are defined to diagnose various phases of diseases, monitor severities of diseases and responses to therapies, or predict prognosis of patients. Disease-specific biomarkers should benefit drug discovery and development, integrate multidisciplinary sciences, be validated by molecular imaging. The opportunities and challenges in biomarker development are emphasized and considered. The Journal of Translational Medicine opens a new Section of Disease Biomarkers to bridge identification and validation of gene or protein-based biomarkers, network biomarkers, dynamic network biomarkers in human diseases, patient phenotypes, and clinical applications. Disease biomarkers are also important for determining drug effects, target specificities and binding, dynamic metabolism and pharmacological kinetics, or toxicity profiles.

【 授权许可】

CC BY   
© Wang; licensee BioMed Central Ltd. 2012